Jun 18, 2015
Cure Forward Receives $15 Million in Series A Financing
CAMBRIDGE, Mass.-- Cure Forward, a privately held Patient Activation Company, announced today that it has secured $15 million in a Series A financing. Apple Tree Partners, which is the sole investor in Cure Forward, officially launches the Company with this commitment. Proceeds will be used to create a multisided technology platform for healthcare built around the science and technology of precision medicine. Cure Forward will harness molecular science to connect patients with relevant information, treatment options, and other patients with similar characteristics, making patient participation in precision healthcare possible.
“We believe there is an entirely new way for people to approach their disease. What Cure Forward will accomplish will be much like Airbnb and Kickstarter, technology platforms that connect people in new ways. We are using scientific information to bring together audiences that previously had no way of finding each other, and when they can, it will unleash enormous value and accelerate cures," said Martin Naley, CEO of Cure Forward.
Cure Forward is currently in a private beta and will launch in September of 2015.
"Apple Tree Partners is dedicated to creating and building transformational healthcare companies. We are thrilled to have supported Cure Forward throughout its journey from a promising concept to a groundbreaking technology platform with a broad range of possibilities, all of which have the potential to improve the lives of so many patients. The world of precision medicine is evolving rapidly and we believe Cure Forward addresses a profound need to connect patients with therapies tailored specifically to their disease. Empowering patients with this access will further accelerate the innovative research needed to advance toward cures and, most importantly, save lives," said Aaron Kantoff, Vice President of Apple Tree Partners and a Director at Cure Forward.
About Apple Tree Partners
Apple Tree Partners (ATP) is a leading venture capital firm dedicated to building healthcare businesses. ATP has deep sector expertise across healthcare services, pharmaceuticals, biotech, and medtech. Founded in 1999, ATP has a well-known history of successfully partnering with management teams and taking the long view as a matter of principle for value creation. ATP raised its fourth fund in 2012 totaling $1.5 billion and is actively funding healthcare innovation. ATP is headquartered in New York City with satellite offices in Princeton, NJ and Cambridge, MA. For more information, please visit our websitewww.appletreepartners.com
About Cure Forward
Cure Forward is a patient activation company bringing together science, community and education, giving patients unprecedented ability to utilize their molecular test data. Through the company’s website, patients can connect with relevant information, treatment options, and other similar patients. Cure Forward makes personalized healthcare accessible and approachable for patients and caregivers, activating their potential for cure or action against their disease. Cure Forward was incubated and launched by Apple Tree Partners, a leading healthcare venture capital firm headquartered in New York City. For more information, visitwww.cureforward.comAll news about Cure Forward